Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc. - Common Stock (NQ:VOR)

21.44 -0.45 (-2.06%)
Streaming Delayed Price Updated: 1:35 PM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 705,588
Open 21.92
Bid (Size) 21.42 (300)
Ask (Size) 21.46 (100)
Prev. Close 21.89
Today's Range 21.34 - 22.00
52wk Range 6.500 - 49.95
Shares Outstanding 66,956,800
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio To Participate in Upcoming September Conferences
From Vor Biopharma
Via GlobeNewswire

Performance

YTD
+84.2%
+84.2%
1 Month
-7.9%
-7.9%
3 Month
+48.0%
+48.0%
6 Month
+62.8%
+62.8%
1 Year
-29.5%
-29.5%

More News

Read More
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
Via The Motley Fool
News headline image
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints David Zaccardelli to Board of Directors
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
Via The Motley Fool
News headline image
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
From Vor Biopharma
Via GlobeNewswire
News headline image
What's Behind The Jump In Vor Biopharma Stock? ↗
Via Benzinga
News headline image
Vor Bio Announces $75 Million Private Placement with TCGX
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
From Vor Biopharma
Via GlobeNewswire

Frequently Asked Questions

Is Vor Biopharma Inc. - Common Stock publicly traded?
Yes, Vor Biopharma Inc. - Common Stock is publicly traded.
What exchange does Vor Biopharma Inc. - Common Stock trade on?
Vor Biopharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vor Biopharma Inc. - Common Stock?
The ticker symbol for Vor Biopharma Inc. - Common Stock is VOR on the Nasdaq Stock Market
What is the current price of Vor Biopharma Inc. - Common Stock?
The current price of Vor Biopharma Inc. - Common Stock is 21.44
When was Vor Biopharma Inc. - Common Stock last traded?
The last trade of Vor Biopharma Inc. - Common Stock was at 09/18/26 01:35 PM ET
What is the market capitalization of Vor Biopharma Inc. - Common Stock?
The market capitalization of Vor Biopharma Inc. - Common Stock is 1.44B
How many shares of Vor Biopharma Inc. - Common Stock are outstanding?
Vor Biopharma Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.